Previous 10 | Next 10 |
2023-09-08 15:00:57 ET More on the markets The Unemployment Rate Just Signaled That A Recession May Occur Within The Next 6 Months High Yield Signal Does Not Align With Bearish Outlook For SPY SPY: The Calm Before The Storm Bulls vs. Bears: SA analysts weigh ...
2023-09-07 11:04:48 ET More on Lilly, Novo, etc. Novo Nordisk: Super Focused Pharma Company For The Long Run Novo Nordisk: Strong Fundamentals Meet Technical Uptrends Eli Lilly And Novo Nordisk: Are Weight Loss Drugs A Global Revolution Or Short-Lived Fad? Se...
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023. Dr. Grogan will be a member of Biogen’s Executive Committee reporting to Christopher ...
2023-09-05 08:27:58 ET Summary Biogen receives FDA approval for Leqembi, a treatment for Alzheimer's Disease, providing a large market opportunity. Biogen's acquisition of Reata Pharmaceuticals brings the potential for significant sales growth with SKYCLARYS, a drug for Friedreich...
2023-09-03 09:03:12 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-09-01 18:29:00 ET More on Biogen Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects Sanofi was mystery suitor in Reata Pharma bidding war - report Biogen And Alzheimer's Disease: Too Early To Celebrate Will Watershed Moment...
2023-08-31 07:22:43 ET More on Sage Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity Sage Therapeutics, Inc. ( SAGE ) Business Update Call (Transcript) Sage Therapeutics' Zuranolone Is A Lost Cause In Depression Market Sage Therapeutic...
2023-08-29 15:24:04 ET RBC Capital said it sees Biogen's stock as undervaluing the long-term prospects of its newly approved Alzheimer's drug Leqembi, with any “better-than-expected acceleration in demand” possibly “reigniting enthusiasm and driving upside” to th...
2023-08-29 10:07:00 ET Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) have a lot in common. Both companies are among the leaders in the biotech industry. Both have deep lineups and pipelines. And both are looking to dominate an area with a severe and growing need for new th...
2023-08-24 19:15:17 ET More on Biogen Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects Biogen Inc. ( BIIB ) Q2 2023 Earnings Call Transcript Biogen And Alzheimer's Disease: Too Early To Celebrate Will Watershed Moment For ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...